FINWIRES · TerminalLIVE
FINWIRES

$CRBP

5 stories mentioning CRBPUpdated 5d ago

Every FINWIRES story that references CRBP, newest first.

Wire

Corbus Pharmaceuticals Completes Patient Visits in Phase 1b Obesity Study

Corbus Pharmaceuticals (CRBP) said Tuesday the last patient completed the final clinical visit in its phase 1b Canyon-1 trial evaluating CRB-913 for the treatment of obesity.The company said the 240-patient dose-finding study remains on track to report topline data in September 2026.CRB-913 is an oral CB1 inverse agonist being developed as a potential treatment for obesity and long-term weight management.Shares of Corbus were up 5% in Tuesday afternoon trading.Price: $9.37, Change: $+0.45, Percent Change: +4.99%

$CRBP
Wire

Mizuho Securities Cuts Price Target on Corbus Pharmaceuticals to $34 From $44, Maintains Outperform Rating

Corbus Pharmaceuticals (CRBP) has an average rating of buy and mean price target of $36.30, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)Price: $8.64, Change: $+0.33, Percent Change: +3.97%

$CRBP
Research

Update: Mizuho Keept Price Target on Corbus Pharmaceuticals to $40, Maintains Outperform Rating

(Updated to keep price target unchanged).Corbus Pharmaceuticals Holdings Inc (CRBP) has an average rating of buy and mean price target of $41.67, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)Price: $10.06, Change: $+0.24, Percent Change: +2.44%

$CRBP
Wire

Mizuho Adjusts Price Target on Corbus Pharmaceuticals to $40 From $39, Maintains Outperform Rating

Corbus Pharmaceuticals Holdings Inc (CRBP) has an average rating of buy and mean price target of $41.67, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)Price: $9.87, Change: $+0.04, Percent Change: +0.46%

$CRBP
Research

Guggenheim Initiates Corbus Pharmaceuticals at Buy With $45 Price Target

Corbus Pharmaceuticals Holdings Inc (CRBP) has an average rating of buy and mean price target of $41.67, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)

$CRBP

Track with the FINWIRES app suite

FolioX
FolioX
Track CRBP in your portfolio
WheelAI
WheelAI
Analyze CRBP options with the wheel strategy
StockInsider
StockInsider
See market sentiment on CRBP